Michael Faia is the Project Management Lead (PML) for JZP150 in Jazz Pharmaceuticals’s Neuroscience franchise. In this role, he established the development and commercialization strategy for Jazz’s fatty acid amide hydrolase (“FAAH”) inhibitor program (JZP150), formed the initial Global Molecule Team (GMT), guided that team through necessary governance activities, advanced JZP150’s lead indication into phase 2, and developed the lifecycle strategy for potential follow-on indications. Michael also serves as Global Program Management Office’s (GPMO’s) business partner to finance.
Michael is a strategic thinker and proven high performer with over 20 years of global experience in product and program management, new product commercialization, and drug development in the pharma-biotech industry. He is an accomplished line and matrix team leader with experience building and developing project management organizations and project teams, managing multi-cultural change programs, establishing strategic direction, executing operational plans, and developing partnerships.
Michael earned his BS and MS degrees in Chemical Engineering from Drexel University, an MS in Quality from Temple University, and an MBA from Pennsylvania State University. Michael is a Pennsylvania licensed Professional Engineer (PE), a Certified Project Manager (PMP), Lean Six Sigma Black Belt (LSS BB), and a Malcolm Baldrige National Quality Award Examiner.